Calm Before The Storm?
It looks like the market activity for GTBP is starting to really pick up and this could be a clear indicator that biotech investors are beginning to take notice! This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders. Now it looks like other outlets have started to look to GTBP for new market potential.
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma’s (GTBP) Board of Directors
Yesterday (4-24) GT Biopharma Inc. (OTCQB: GTBP) announced that Dr. Peter Kiener will join GT Biopharma’s Board of Directors, effective immediately. Once again, GTBP is adding key industry talent and Dr. Kiener’s experience is strong in our opinion! It includes roles at MedImmune LLC, Bristol-Myers Squibb, BioLogix Inc., Ambrx, and was most recently the Chief Scientific Officer at Sucampo, which was acquired by Mallinckrodt in February 2018 for approximately $1.2 billion!
Disclaimer: Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by a GT Biopharma Inc. for a period beginning May 1, 2018 and ending May. 31, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here